PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth exceeding 1.5x Biotechnology median of 0.86%. Jim Chanos would check for wasteful spending.
-38.56%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-7.06%
Operating expenses reduction while Biotechnology median is 3.90%. Seth Klarman would investigate advantages.
-7.06%
Total costs reduction while Biotechnology median is 3.69%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
D&A reduction while Biotechnology median is 0.28%. Seth Klarman would investigate efficiency.
7.02%
EBITDA growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth exceeding 1.5x Biotechnology median of 1.97%. Jim Chanos would check for issues.
10.36%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS change of 28.30% versus flat Biotechnology. Walter Schloss would verify quality.
28.30%
Diluted EPS change of 28.30% versus flat Biotechnology. Walter Schloss would verify quality.
24.68%
Share count reduction below 50% of Biotechnology median of 0.80%. Jim Chanos would check for issues.
24.68%
Diluted share reduction below 50% of Biotechnology median of 1.01%. Jim Chanos would check for issues.